JP2024534496A5 - - Google Patents
Info
- Publication number
- JP2024534496A5 JP2024534496A5 JP2024517415A JP2024517415A JP2024534496A5 JP 2024534496 A5 JP2024534496 A5 JP 2024534496A5 JP 2024517415 A JP2024517415 A JP 2024517415A JP 2024517415 A JP2024517415 A JP 2024517415A JP 2024534496 A5 JP2024534496 A5 JP 2024534496A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- combinations
- mrna
- fusion protein
- grna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246689P | 2021-09-21 | 2021-09-21 | |
| US63/246,689 | 2021-09-21 | ||
| US202263352530P | 2022-06-15 | 2022-06-15 | |
| US63/352,530 | 2022-06-15 | ||
| PCT/US2022/076723 WO2023049707A1 (en) | 2021-09-21 | 2022-09-20 | Mrna regulon therapy for the treatment of haploinsufficiency disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534496A JP2024534496A (ja) | 2024-09-20 |
| JP2024534496A5 true JP2024534496A5 (https=) | 2025-09-10 |
Family
ID=85719677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517415A Pending JP2024534496A (ja) | 2021-09-21 | 2022-09-20 | ハプロ不全障害の処置のためのｍＲＮＡレギュロン療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250135035A1 (https=) |
| EP (1) | EP4404953A4 (https=) |
| JP (1) | JP2024534496A (https=) |
| KR (1) | KR20240099184A9 (https=) |
| AU (1) | AU2022349620A1 (https=) |
| CA (1) | CA3232214A1 (https=) |
| MX (1) | MX2024003412A (https=) |
| WO (1) | WO2023049707A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023212687A1 (en) * | 2022-04-29 | 2023-11-02 | The Johns Hopkins University | Systems for enhancing mrna expression and uses thereof |
| EP4671372A3 (en) | 2024-01-29 | 2026-03-11 | Arnatar Therapeutics, Inc | Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015221026A (ja) * | 2014-05-23 | 2015-12-10 | 公立大学法人名古屋市立大学 | 人工合成ｍＲＮＡの翻訳効率化方法 |
| EP3365454A1 (en) * | 2015-10-20 | 2018-08-29 | 10X Genomics, Inc. | Methods and systems for high throughput single cell genetic manipulation |
| US11730828B2 (en) * | 2017-02-07 | 2023-08-22 | The Regents Of The University Of California | Gene therapy for haploinsufficiency |
| KR102318434B1 (ko) * | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| CN115023499A (zh) * | 2019-08-16 | 2022-09-06 | 麻省理工学院 | 使用CRISPR/Cas13的靶向反式剪接 |
-
2022
- 2022-09-20 EP EP22873808.4A patent/EP4404953A4/en active Pending
- 2022-09-20 US US18/693,636 patent/US20250135035A1/en active Pending
- 2022-09-20 CA CA3232214A patent/CA3232214A1/en active Pending
- 2022-09-20 KR KR1020247012661A patent/KR20240099184A9/ko active Pending
- 2022-09-20 JP JP2024517415A patent/JP2024534496A/ja active Pending
- 2022-09-20 WO PCT/US2022/076723 patent/WO2023049707A1/en not_active Ceased
- 2022-09-20 AU AU2022349620A patent/AU2022349620A1/en active Pending
- 2022-09-20 MX MX2024003412A patent/MX2024003412A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2572811T3 (es) | Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos | |
| JP4688092B2 (ja) | 活性型ＴＧＦ−βが濃縮されたタンパク質画分を得る方法、タンパク質画分および治療的適用 | |
| EP3263122B1 (en) | Peptide for preventing hearing loss, and composition comprising same | |
| JP2024534496A5 (https=) | ||
| JP5784877B2 (ja) | 喘息治療のためのフマル酸誘導体含有薬剤 | |
| JP2002523028A (ja) | 安定な低酸素誘導性因子１αおよび使用方法 | |
| CN102245629B (zh) | 修饰的淀粉状蛋白β肽 | |
| CN112694518A (zh) | 一种肾损伤分子-1（Kim-1）靶向多肽及其应用 | |
| JP2002515445A (ja) | 細胞毒性活性を有する医薬品調製のためのｈｍｇ蛋白質の使用 | |
| CN100413888C (zh) | 可溶性多肽 | |
| JP2001510981A (ja) | Ｉｘ型コラーゲンおよびキメラ | |
| US8071716B2 (en) | Thymus-specific protein | |
| CN118252913A (zh) | 多肽偶联物及其在射血分数保留的心衰中的应用 | |
| WO2011116245A2 (en) | Methods of treating inflammation | |
| RS49733B (sr) | Soli bpc peptida sa organo- zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena | |
| JP2008208096A (ja) | クラゲタンパク質由来の新規ペプチドとその用途 | |
| JP2012229165A (ja) | 抗炎症剤および抗炎症剤の製造方法 | |
| JP2021518392A5 (https=) | ||
| WO2023097292A2 (en) | Compositions and methods for treating cancer by targeting endothelial cells having upregulated expression of transmembrane molecules | |
| US11084879B2 (en) | Compositions and methods for treating pancreatitis and pain with death receptor agonists | |
| JP4216950B2 (ja) | インターロイキン−１８結合蛋白質 | |
| JP2025500508A5 (https=) | ||
| CN112679595B (zh) | 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用 | |
| JP5439007B2 (ja) | 血管内皮細胞増殖因子阻害剤及び抗癌剤 | |
| JP3031693B2 (ja) | アンギオテンシン変換酵素阻害剤含有組成物の製造方法 |